Two studies: another amyloid-directed therapy (crenezumab) does not improve cognition in early Alzheimer disease

Clinical Question

Does crenezumab improve measures of cognition in adults with Alzheimer disease?

Bottom line

These studies provide additional evidence of the inability of amyloid-directed therapies to improve outcomes in adults with mild Alzheimer disease. A recent study reports that lecanemab slows the rate of cognitive loss as measured by various scales. However, improvement in clinically relevant outcomes have not yet been reported. 1b

Study design: Randomized controlled trial (double-blinded)

Funding: Industry

Setting: Outpatient (specialty)

Reviewer

Henry C. Barry, MD, MS
Professor
Michigan State University
East Lansing, MI


Discuss this POEM


Comments

Anonymous

Biologicals against amyloid…?

We really actually don’t know the pathology of AD and targeting amyloid may be the wrong approach

ARUP KUMAR DHARA

Impact assessment

Very good